Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare

Metastatic colon cancer (mCC) patients often receive multiple lines of chemotherapy/biological treatment (TX), yet subsequent TX lines have not been sufficiently examined using SEER-Medicare data. We developed an algorithm that identifies the number and type of TX lines received by mCC patients. The...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Medical care Ročník 53; číslo 8; s. e58
Hlavní autori: Bikov, Kaloyan A, Mullins, C Daniel, Seal, Brian, Onukwugha, Eberechukwu, Hanna, Nader
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.08.2015
Predmet:
Age Factors
Aged
Aged, 80 and over
Algorithms
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy, Adjuvant
Colonic Neoplasms - drug therapy
Colonic Neoplasms - epidemiology
Female
Humans
Male
Medicare
Neoplasm Metastasis
SEER Program - organization & administration
United States - epidemiology
United States
ISSN:1537-1948, 1537-1948
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Metastatic colon cancer (mCC) patients often receive multiple lines of chemotherapy/biological treatment (TX), yet subsequent TX lines have not been sufficiently examined using SEER-Medicare data. We developed an algorithm that identifies the number and type of TX lines received by mCC patients. The algorithm rules for detecting TX lines were developed a priori and applied to SEER-Medicare data for 7951 elderly mCC patients, diagnosed in 2003-2007 and followed through 2009. Statistical analysis estimated the relationship between the number of treatments received and patient characteristics. Sensitivity analyses examined how results changed when different algorithm rules were used. Only 41% (3266) of mCC patients received any chemotherapy/biologics treatment; 1440 (18% of all, 44% of treated) and 274 (3% of all, 8% of treated) received second-line and third-line treatment, respectively. Initial and subsequent treatment regimens varied widely. Results were robust to alterations in the algorithm. The number of drugs used to treat cancer patients has increased during the past decade. Patients may have several TX lines with complex regimens. More guidance is needed with regard to identifying and studying these interventions using SEER-Medicare data. By proposing 1 approach to categorizing TX lines for mCC patients, we hope to empower the scientific community and to advance the use of SEER-Medicare data for health outcomes research.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1537-1948
1537-1948
DOI:10.1097/MLR.0b013e31828fad9f